News | May 31, 2021
Multiple catalysts ahead for Cadila Healthcare: HDFC Securities
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
The patients can check to see if the product purchased by them is genuine or not by scratching the surface and verifying the code through the app or the website
The company has registered total income of Rs. 3,847 crores for Q4 FY21, up by 3% on a y-o-y basis from Rs. 3,752 crores registered during corresponding period of the previous year
The company reported net profit for FY21 at Rs. 2,903.8 crore, lower by 23% over last year
Revenue from operations for the year ended March 31, 2021 is ?2,239 crore
This marks Glenmark's first synthetic decapeptide injectable approval
NATCO and Arrow shall launch the product on agreed-upon launch dates in the future.
We focused on developing the product last year but now our focus is on ramping up our manufacturing capacity
Number of approved manufacturing sites of Remdesivir in the country has increased from 22 sites to 60
The company will provide one crore tablets every week, starting from 12th May 2021, aggregating to 16 crore tablets worth Rs. 8 crores over the next 4 months
Subscribe To Our Newsletter & Stay Updated
